Search research articles
Contact Us
Filters
Showing results (61-70 of 94) with videos related to
Page
of 10
Sort By:
Cancer Cell
|
June 5, 2018
The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma
Matthew J McBride, John L Pulice, Hannah C Beird, et al.
Biorxiv : the Preprint Server for Biology
|
August 12, 2025
CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma
Susu Zhang, Kathleen Engel, Assil Fahs, et al.
Journal of Clinical Medicine
|
April 30, 2021
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
Holly L Pacenta, Wendy Allen-Rhoades, David Langenau, et al.
Molecular Cancer Therapeutics
|
December 4, 2025
Activity of direct KRAS(G12C) inhibitors in preclinical models of pediatric cancer
Hannah E Price, Stacey Stauffer, Hyun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2023
Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Srivandana Akshintala, R Taylor Sundby, Donna Bernstein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 15, 2022
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe
Simone Hettmer, Corinne M Linardic, Anna Kelsey, et al.
Science Translational Medicine
|
July 6, 2018
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma
Marielle E Yohe, Berkley E Gryder, Jack F Shern, et al.
Cancers
|
July 13, 2024
Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma
Stacey Stauffer, Jacob S Roth, Edjay R Hernandez, et al.
JAMA Dermatology
|
August 16, 2023
Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome
Michael R Sargen, Jung Kim, Thomas P Potjer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 12, 2025
Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group
Jacquelyn N Crane, David P Douglass, Sapna Oberoi, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 94) with videos related to
Sort By:
Page
of 10
Cancer Cell
|
June 5, 2018
The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma
Matthew J McBride, John L Pulice, Hannah C Beird, et al.
Biorxiv : the Preprint Server for Biology
|
August 12, 2025
CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma
Susu Zhang, Kathleen Engel, Assil Fahs, et al.
Journal of Clinical Medicine
|
April 30, 2021
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
Holly L Pacenta, Wendy Allen-Rhoades, David Langenau, et al.
Molecular Cancer Therapeutics
|
December 4, 2025
Activity of direct KRAS(G12C) inhibitors in preclinical models of pediatric cancer
Hannah E Price, Stacey Stauffer, Hyun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2023
Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Srivandana Akshintala, R Taylor Sundby, Donna Bernstein, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 15, 2022
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe
Simone Hettmer, Corinne M Linardic, Anna Kelsey, et al.
Science Translational Medicine
|
July 6, 2018
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma
Marielle E Yohe, Berkley E Gryder, Jack F Shern, et al.
Cancers
|
July 13, 2024
Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma
Stacey Stauffer, Jacob S Roth, Edjay R Hernandez, et al.
JAMA Dermatology
|
August 16, 2023
Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome
Michael R Sargen, Jung Kim, Thomas P Potjer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 12, 2025
Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's Oncology Group
Jacquelyn N Crane, David P Douglass, Sapna Oberoi, et al.
Page
of 10